Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 9/20 | 0.69 |
| ▸ | CNR1 | P21554 | 5/20 | 0.46 |
| ▸ | CNR2 | P34972 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8143705 | 0.81 | CACNA1B (1.00) | CACNA1BCNR1CNR2NR1I2 | |
| SCHEMBL8150545 | 0.81 | CACNA1B (0.76) | CACNA1BCNR1CNR2NR1I2 | |
| SCHEMBL8153141 | 0.78 | CACNA1B (0.77) | CACNA1BCNR1CNR2KDM4EALDH1A1 | |
| SCHEMBL8161884 | 0.78 | CACNA1B (1.00) | CACNA1BNR1I2 | |
| SCHEMBL8148540 | 0.73 | CACNA1B (0.72) | CACNA1BKDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL11686661 | 0.72 | CACNA1B (0.53) | CACNA1BKDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL11688017 | 0.71 | CACNA1B (0.51) | CACNA1BKDM4EALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL8156545 | 0.70 | CACNA1B (0.71) | CACNA1BCNR1CNR2KDM4EALDH1A1 | |
| SCHEMBL8148440 | 0.69 | CACNA1B (0.68) | CACNA1BHSD17B10SMN1; SMN2NR1I2LMNA | |
| SCHEMBL8156333 | 0.68 | NR1I2 (0.75) | CACNA1BNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| WO-2008133867-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, CACNA1S, TRPV2 | CACNA1B 13/4885CNR1 173/4885CNR2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.